Assessing the Global Tendency of COVID-19 Outbreak

Liu, Qinghe; Liu, Zhicheng; Zhu, Junkai; Zhu, Yuhao; Li, Deqiang; Gao, Zefei; Zhou, Liuling; Tang, Yuanbo; Zhang, Xiang; Yang, Junyan; Wang, Qiao

doi:10.1101/2020.03.18.20038224

Cited by 30 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As of April 12, 2020, the cases of COVID-19 have been reported in 211 countries and territories worldwide, with a total of 1,696,588 confirmed cases and 105,952 deaths [4] . Moreover, the number of confirmed cases continues to grow at a rapid rate, including United States [5] . To date, the outbreak in China has been effectively controlled by widespread testing, quarantine of cases, contact tracing and social distancing [6] .…”

Section: Introductionmentioning

confidence: 99%

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Wang

Guo

Xin

et al. 2020

Clinical Infectious Diseases

266

232

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) is a pandemic with no specific antiviral treatments or vaccines. There is an urgent need for exploring the neutralizing antibodies from patients with different clinical characteristics. Methods A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. Antibodies were determined with a modified cytopathogenic neutralization assay (NA) based on live severe acute respiratory syndrome coronavirus 2 and enzyme-linked immunosorbent assay (ELISA). The dynamics of neutralizing antibody levels at different time points with different clinical characteristics were analyzed. Results The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till days 41–53. The total geometric mean titer was 1:163.7 (95% confidence interval [CI], 128.5–208.6) by NA and 1:12 441.7 (95% CI, 9754.5–15 869.2) by ELISA. The antibody level by NA and ELISA peaked on days 31–40 since onset, and then decreased slightly. In multivariate generalized estimating equation analysis, patients aged 31–45, 46–60, and 61–84 years had a higher neutralizing antibody level than those aged 16–30 years (β = 1.0470, P = .0125; β = 1.0613, P = .0307; β = 1.3713, P = .0020). Patients with a worse clinical classification had a higher neutralizing antibody titer (β = 0.4639, P = .0227). Conclusions The neutralizing antibodies were detected even at the early stage of disease, and a significant response was shown in convalescent patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Wang

Guo

Xin

et al. 2020

Clinical Infectious Diseases

266

232

View full text Add to dashboard Cite

show abstract

“…As of April 12, 2020, the cases of COVID-19 have been reported in 211 countries and territories worldwide, with a total of 1696588 confirmed cases and 105952 deaths [4] . Moreover, the number of confirmed cases continues to grow at a rapid rate, including United States [5] . To date, the outbreak in China has been effectively controlled by widespread testing, quarantine of cases, contact tracing and social distancing [6] .…”

Section: Introductionmentioning

confidence: 99%

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

Wang

Guo

Xin

et al. 2020

Preprint

138

137

View full text Add to dashboard Cite

Background. COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging. Methods.A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. The presence of neutralizing antibody was determined with a modified cytopathogenic assay based on live SARS-CoV-2. The dynamics of neutralizing antibody levels at different with different clinical characteristics were analyzed.Results. The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), and the antibody level was highest during day 31-40 since onset, and then decreased slightly. Individual differences in changes of antibody levels were observed among 8 representative convalescent patients. In multivariate GEE analysis, patients at age of 31-60 and 61-84 had a higher antibody level than those at age of 16-30 (β=1.0518, P=0.0152; β =1.3718, P=0.0020). Patients with a worse clinical classification had a higher antibody titer (β=0.4639, P=0.0227).Conclusions. The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Moreover, changes on antibody levels ware individual specific.

show abstract

“…Interdisciplinary research has been actively conducted to mitigate the spread of COVID-19 and its adverse impacts on society. Epidemiologic measurements have been explored to identify the dynamics of disease regarding the spread risk and the effect of human mobility [3][4][5][6][7][8][9][10]. Besides, since the mobility restrictions are considered as a critical factor to prevent the disease spread, studies have assessed its impact [11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Human mobility trends during the early stage of the COVID-19 pandemic in the United States

et al. 2020

View full text Add to dashboard Cite

In March of this year, COVID-19 was declared a pandemic, and it continues to threaten public health. This global health crisis imposes limitations on daily movements, which have deteriorated every sector in our society. Understanding public reactions to the virus and the non-pharmaceutical interventions should be of great help to fight COVID-19 in a strategic way. We aim to provide tangible evidence of the human mobility trends by comparing the day-by-day variations across the U.S. from January 2020 to early April 2020. Large-scale public mobility at an aggregated level is observed by leveraging mobile device location data and the measures related to social distancing. Our study captures spatial and temporal heterogeneity as well as the sociodemographic variations and teleworking trends regarding the pandemic propagation and the non-pharmaceutical mobility interventions. All metrics adapted capture decreased public movements after the national emergency declaration. The population staying home has increased in all states before the stay-at-home mandates implemented and becomes more stable after the order with a smaller range of fluctuation. The public had been taking active responses, voluntarily staying home more, to the in-state confirmed cases while the stay-at-home orders stabilize the variations. As the estimated teleworking rates also continue to incline throughout the study period, the teleworking trend can be another driving factor for the growing stay-at-home population. We confirm that there exists overall mobility heterogeneity between the income or population density groups. The study suggests that public mobility trends are in line with the government message urging to stay home. We anticipate our data-driven analysis offers integrated perspectives and serves as evidence to raise public awareness and, consequently, reinforce the importance of social distancing while assisting policymakers.

show abstract

Assessing the Global Tendency of COVID-19 Outbreak

Cited by 30 publications

References 24 publications

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

Human mobility trends during the early stage of the COVID-19 pandemic in the United States

Contact Info

Product

Resources

About